Roche Holding AG ROG
News
FDA Approves Genentech’s Vabysmo Prefilled Syringe (PFS) for Three Leading Causes of Vision Loss
Roche to halt lung-cancer drug trial after disappointing data
Roche to Halt Lung Cancer Trial After Results Miss Goals
Genentech Provides Update on Phase II/III SKYSCRAPER-06 Study in Metastatic Non-Squamous Non-Small Cell Lung Cancer
Roche's Multiple Sclerosis Injection Gets EU Approval
Sarepta Shares Soar 37% Following Expanded Approval for Elevidys
Roche Teams Up With Ascidian Therapeutics for RNA Gene Editing Deal
Roche receives FDA clearance on its digital pathology solution for diagnostic use
Genentech’s Phase III STARGLO Study Demonstrates Columvi Significantly Extends Survival in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Five-year Data for Genentech’s Evrysdi Show the Majority of Treated Children With a Severe Form of Spinal Muscular Atrophy (SMA) Achieved or Maintained the Ability to Sit, Stand or Walk
Roche Breast-Cancer Drug Gets Priority Review in the U.S.
FDA Grants Priority Review to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
Roche and Hitachi High-Tech extend their 46-year partnership, paving the way for further breakthroughs in diagnostic testing
Roche, LumiraDx Deal Probed by U.K. Competition Watchdog
Roche's Inavolisib Breast Cancer Treatment Gets FDA Breakthrough Therapy Designation
FDA Grants Breakthrough Therapy Designation to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation
U.K. Competition Watchdog Weighs Potential Impact of Roche-LumiraDx
Roche ramps up obesity-drug competition with early-stage trial results
Roche Shares Climb After Weight-Loss Drug Shows Efficacy in Early-Stage Trial — Update